B-type Natriuretic Peptide Enhances Fibrotic Effects via Matrix Metalloproteinase-2 Expression in the Mouse Atrium in vivo and in Human Atrial Myofibroblasts in vitro
博士 === 國防醫學院 === 醫學科學研究所 === 107 === B-type natriuretic peptide (BNP) was approved by the US Food and Drug Administration in 2001 for the treatment of heart failure. However, the effects of BNP in clinical applications are controversial and uncertain. Recently, study indicated that high BNP levels...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | en_US |
| Published: |
2019
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/26m77m |